Phathom Pharma Climbs 45% In 4 Days As Lead Drug Advances Into Phase III

Shares of Phathom Pharmaceuticals Inc. (PHAT) have gained an impressive 45% over the last four trading days, thanks to the progress in the development of its lead and sole drug Vonoprazan.

from RTT - Biotech https://ift.tt/2Sm9p83
via IFTTT